Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HOUSTON, May 19, 2020 /PRNewswire/ -- Mark Lanier, the trial lawyer who earned the largest jury verdict to date on behalf of consumers who have developed cancer from talc-based cosmetics, welcomed an announcement by Johnson & Johnson (NYSE: JNJ) that it would cease manufacturing products...

Attorney Mark Lanier 'Gratified but Not Yet Satisfied' by Johnson & Johnson Decision to Discontinue Talc-Based Baby Powder

The phamaceutical giant continues to defend the product’s safety, but says demand for the talc-based powder is declining

Johnson & Johnson (JNJ) to stop selling baby powder in US and Canada

Thousands of lawsuits claim the product causes cancer, though the company denies this.

Johnson & Johnson  Discontinues Talc-Based Baby Powder In US And Canada

Dow Jones stock Johnson & Johnson said Tuesday it's discontinuing its baby powder in the U.S. and Canada as demand dives amid lawsuits claiming the talc-based products cause cancer.

Johnson & Johnson Pulls Baby Powder From U.S., Canada As Demand Plummets

Johnson & Johnson Inc. JNJ, -0.99% said late Tuesday it will stop selling talc-based baby powder in North America following a flurry of lawsuits alleging the product causes cancer.

J&J pulls sale of talc-based baby powder in North America

Johnson & Johnson on Tuesday announced that it would stop selling its talc-based Johnson’s Baby Powder in the United States and Canada, saying it was part of a broad reassessment of its consumer product portfolio prompted by the coronavirus pandemic.

Johnson & Johnson to stop selling talc-based Johnson's Baby Powder in U.S., Canada

J&J says it is discontinuing its talc-based baby powder in the United States and Canada as demand fell in light of mounting lawsuits that said it caused cancer.

Johnson & Johnson discontinues talc-based baby powder in US and Canada

A double-sided antibody with blockbuster potential shrank tumors for relapsed multiple myeloma patients who have run out of treatment options.

Johnson & Johnson's Oncology Team Posts Promising Cancer Trial Results

Emergent BioSolutions

Which of these COVID-19 partners is the better pick? Here's how J&J and Emergent stack up against each other.

Better Coronavirus Stock: Johnson & Johnson or Emergent BioSolutions?

Prem Watsa (Trades, Portfolio)'s Fairfax Financial Holdings sold shares of the following stocks during the first quarter of 2020.

Fairfax Financial Sells Johnson & Johnson

Johnson & Johnson is hoping to tackle the new form of coronavirus with a vaccine, but the pharma giant is still facing litigation challenges. Is JNJ stock a buy right now?

Is JNJ Stock A Buy As Pharma Giant Targets A Coronavirus Vaccine?

Johnson & Johnson’s stock has outperformed the broader markets as well as some of its peers over the last few weeks. While J&J stock grew 32% since the recent lows of March 23, the S&P 500 gained 26%.

Why Johnson & Johnson Looks Undervalued At $145

The startup aims to take on bluebird bio and Bristol Myers Squibb with its CAR-T therapy targeting BCMA for multiple myeloma.

Legend Biotech Makes Plans to IPO With Backing From Johnson & Johnson

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?

Johnson & Johnson (JNJ) Down 0.4% Since Last Earnings Report: Can It Rebound?

Colgate-Palmolive

Duke Energy

General Dynamics

PepsiCo

Public Storage

QUALCOMM

Dividend investors face turbulent conditions as blue-chip companies slash payouts. But these seven dividend stocks will still pay the bills.

7 Dividend Stocks That You Can Still Bank On

American States Water

Visa

If you fear a recession and are a risk-averse investor, these stocks won't let you down.

3 Great Stocks for  Low-Risk Investors

Apple

Costco

Newmont Mining

Procter & Gamble

Not everything is bad in terms of dividend announcement. These companies announced/raised dividends amid COVID-19 pandemic.

Is Fear Stemming From Dividend Cuts Overblown? Stocks to Gain

BioNTech SE

GlaxoSmithKline

Inovio Pharmaceuticals

Moderna

Novavax

Pfizer

Sanofi

Sinovac Biotech

Is There A Safer Way to Invest in a Coronavirus Vaccine?

Too much diversification could bad for your portfolio right now.

This 1 Industry Is The Safest Place to Park Your Cash Today

Medtronic

The healthcare sector is a safe space for investors looking for outstanding returns in difficult times.

Coronavirus Chaos Makes These 2 Healthcare Dividend Aristocrats Look Good

Disney

General Mills

AT&T

Texas Instruments

Exxon Mobil

Remembering these simple rules will help you separate the winners from the losers.

8 Facts About High-Yield Dividend Stocks Every Investor Should Know

AbbVie

NextEra Energy

These dividend stocks are built to last years and pay out regularly to boost your retirement income.

3 Dividend Stocks  Perfect for Retirees

Adobe

A handful of the market's biggest names are poised to shrug off the effects of COVID-19 and continue to power their way forward.

3 Top Large-Cap  Stocks to Buy in May

Abbott Labs

Eli Lilly

Healthcare stocks are pulling the market higher today. Here are three of the best stocks to buy in the sector right now.

News for Johnson & Johnson Stock (JNJ)